Loading
journalsJournal
Lung cancer
The main specialist journal for lung cancer and other chest tumours, publishing trials, translational studies and reviews. Read by thoracic oncologists, surgeons and pulmonologists.
Also called: Lung cancer : journal of the International Association for the Study of Lung CancerLung Cancer (Amsterdam, Netherlands)
Overview
Lung Cancer is published by Elsevier and is described on its ScienceDirect page as an international journal for lung cancer and other thoracic malignancies and an official journal of the European Society for Medical Oncology, the ETOP IBCSG Partners Foundation and the British Thoracic Oncology Group; NLM catalogues it under its older subtitle as the journal of the International Association for the Study of Lung Cancer. It covers the clinical, translational and basic science of malignancies of the lung and chest region, welcoming original research articles, early reports, review articles, editorials and correspondence on prevention, epidemiology and aetiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined modality treatment and outcomes. Elsevier lists it as supporting open access with an open archive, with a choice of open access (article publishing charge) or subscription publication. NLM records it as starting in 1985 and currently indexed in MEDLINE.
Publisher
Elsevier · European Society for Medical Oncology, ETOP IBCSG Partners Foundation and British Thoracic Oncology Group
Scope
thoracic oncology
Access model
hybrid
Founded
1985
ISSN
0169-5002
observational20260 citations
A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF V600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study
This is the paper Europe PMC returns for registry id NCT05195632 with the most citations, so it is the natural first reading for anyone following the OCEANII trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
rct20260 citations
FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer
For a patient weighing the FLAURA2 regimen against osimertinib alone, the extra toxicity is front-loaded: the hardest months are the four induction cycles, and once pemetrexed stops the profile returns to that of osimertinib by itself. Kidney function deserves watching during pemetrexed maintenance.
rct202276 citations
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study
A second publication from the ORIENT-11 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
Nei-Min Chu
President (院長) of Koo Foundation Sun Yat-Sen Cancer Center
Medical oncologyHaematology-oncologyLung cancer
Medical oncologist who became President of Taipei's Koo Foundation Sun Yat-Sen Cancer Center in late 2024 after nearly three decades on its staff.
Weimin Li
President, West China Hospital; Professor of Respiratory Medicine
Lung cancer early detectionRespiratory medicineAI in imaging
Leads one of the world's largest hospitals and its lung cancer screening and AI programmes.
observationalLung cancer 20260 citations
A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF V600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study
This is the paper Europe PMC returns for registry id NCT05195632 with the most citations, so it is the natural first reading for anyone following the OCEANII trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
rctLung Cancer 20260 citations
FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer
For a patient weighing the FLAURA2 regimen against osimertinib alone, the extra toxicity is front-loaded: the hardest months are the four induction cycles, and once pemetrexed stops the profile returns to that of osimertinib by itself. Kidney function deserves watching during pemetrexed maintenance.
rctLung cancer 202276 citations
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study
A second publication from the ORIENT-11 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
Similar pages
- JournalThoracic cancer
Shares Thymoma and thymic carcinoma, Mesothelioma, PubMed & Europe PMC, Small-cell lung cancer.
- TrialPhase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung
Shares A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF V600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study, Small-cell lung cancer, Non-small-cell lung cancer.
- PersonRolf A. Stahel
Shares ETOP IBCSG Partners Foundation, Mesothelioma, Non-small-cell lung cancer.
- InstitutionKoo Foundation Sun Yat-Sen Cancer Center
Shares Nei-Min Chu, Non-small-cell lung cancer.
- TrialORIENT-11
Shares Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study, Non-small-cell lung cancer.
- JournalZhongguo fei ai za zhi
Shares PubMed & Europe PMC, Small-cell lung cancer, Non-small-cell lung cancer.
- PersonKaren Kelly
Shares Mesothelioma, Small-cell lung cancer, Non-small-cell lung cancer.
- PersonMichael Boyer
Shares Mesothelioma, Small-cell lung cancer, Non-small-cell lung cancer.
cancers
companies
collections
people
key papers
A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF V600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II studyFinal overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 studyFLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer